The DOI matches its Crossref record.
Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?
Abstract
Cannabis is widely used recreationally and for symptomatic relief in a number of ailments. However, cannabis has been implicated as a risk factor for the development of psychotic illness. For forty years researchers have utilised intravenous preparations of Δ9- THC, as well as several other phytocannabinoids, in a laboratory setting. The intravenous route has the most reliable pharmacokinetics, reducing inter-individual variation in bioavailability and is well suited for the delivery of synthetic compounds containing a sole pharmacological moiety. Given the association between cannabinoids and psychotic illness, there has been a resurgence of interest in experimental studies of cannabinoids in humans, and the intravenous route has been employed. Here in a critical review, we appraise the major findings from recent intravenous cannabinoid studies in humans and trace the historical roots of this work back to the 1970’s. Keywords: Cannabis, Intravenous, delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabivarin, cannabidiol, THC, psychotic illness, phytocannabinoids, pharmacokinetics, intravenous route.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CBD acts yet as an important entourage compound as it is able to reduce the side effects of THC (Englund et al., 2012), and may thereby increase the safety of Cannabis-based extracts.”
From Cannabis sativa: The Plant of the Thousand and One Molecules (2016) · cites this paper as Englund et al., 2012
Citations
Cites
Still being checked.
Cited by
Cannabis sativa: The Plant of the Thousand and One Molecules
Andre, C. M., Hausman, J.-F., & Guerriero, G. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00019 · Cited by 1,544
“The sum of the THC and CBD fractions (without reporting the distinct amounts of each of them) in hemp stem wood and bark extractives was 2 and 1%, respectively, which represented 0.003 and 0.0005% of the total fiber content.”
BackgroundInfluentialIversen, L. L. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328240.001.0001 · Cited by 212
Englund, A., Atakan, Z., Kralj, A., Tunstall, N., Murray, R. M., & Morrison, P. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115615104 · Cited by 94
Self-citationGanesh, S., Cortes-Briones, J., Ranganathan, M., Radhakrishnan, R., Skosnik, P. D., & D’Souza, D. C. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa031 · Cited by 49
Panlilio, L. V., & Justinová, Z. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.193 · Cited by 39
Metadata
- Authors
- Englund, A., M. Stone, J., & D. Morrison, P.
- Affiliations
- King's College London (GB)
- Corresponding author
- Englund, Amir
- ORCID
- Englund, Amir
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-09-12
- Volume
- 18
- Issue
- 32
- Pages
- 4906-4914
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2149237663
- Cited by
- 28
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 8 · 2017: 1 · 2016: 2 · 2015: 2
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- delta-9-tetrahydrocannabinol, cannabidiol, phytocannabinoids, psychosis, cannabis and psychosis, pharmacokinetics
- MeSH terms
- Arm, Humans, Injections, Intravenous, Dronabinol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies? https://app.cochat.ai/papers/10.2174/138161212802884618
- The paper
- Englund, A., M. Stone, J., & D. Morrison, P. (2012). Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies? Current Pharmaceutical Design. https://doi.org/10.2174/138161212802884618
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.